Neuroimmunology Program - IDIBAPS

Research areas

Pathogenesis and Novel Therapies in Multiple Sclerosis

|Alt Image Group research area|

Our work is focused in understanding the causes and mechanisms leading to brain damage in Multiple Sclerosis. In order to achieve this goal we apply the tools of systems biology and brain imaging to dissect the immunological mechanisms leading to brain damage. In doing so, we apply a multidisciplinary approach involving neurologists, ophthalmologists, bioinformaticians, engineers and biologists, that all contribute to the research program.

Our team has a strong translational interest and is highly focused in innovation. As such we work in translating our research into new tools for treating MS. For example we are developing several new neuroprotective therapies for MS and other brain diseases by targeting different pathways such as the polyamine pathway or the neurotrophin pathway.

In the lab we perform the preclinical development of new therapies in collaboration with spin-off companies: Bionure, Mint-Labs and Fractalmed and at the hospital we will perform the clinical development by carrying out clinical trials. We are also developing several new diagnostic tools such as molecular imaging of the retina, new software for quantifying axonal damage or new biomarkers based in gene expression and metabolomics for predicting the course of the disease.

Finally, we aim to translate our discoveries in collaboration with leading centers around the world in the management of patients with MS, developing personalized medicine by applying computational models in combination with molecular, imaging and clinical databases using advanced computational tools. Most of these efforts are conducted in collaboration with the Spanish MS network from the Instituto de Salud Carlos III and within several European grants and international collaborations.



New therapies for MS and NMO
  • Antigen specific tolerization
    • Dendritic cell tolerization
    • Nanoparticle tolerization
  • Neuroprotective drugs
    • Trophic factor mimetics: BN201
    • Mathylthioadenosine
Systems biology, precision medicine and big data (Electronic Medical records) in MS
Connectms: Brain connectomics: modeling disconnection syndrome in Multiple Sclerosis

We aim to analyze structural and functional connectivity networks in patients with MS in order to improve our understanding about the organization of brain networks using MS lesions as a perturbation to the networks. In addition, we aim to use the analysis of brain connectivity as biomarkers of the disease.


Combims: A novel drug discovery method based on systems biology: combination therapy and biomarkers for Multiple Sclerosis

CombiMS aims to develop a computational method that will help to discover new combinations of drugs for Multiple Sclerosis (a classic complex disease) based on medical and scientific knowledge, and using computer simulations.


Sys4MS:Personalizing health care in Multiple Sclerosis using systems medicine Tools

The Sys4MS consortium aims to develop new tools based on systems medicine to improve and personalize the management of patients with a complex disease, Multiple Sclerosis (MS). This requires developing mathematical models into which clinical information and ‘omics data from diverse sources can be integrated, and which can be used to generate algorithms that can predict the disease course and future disability in specific subgroups of MS patients, as well as aiding the selection of the best therapy for each individual.

Web: more info about Sys4MS